中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2013年
19期
2967-2969
,共3页
泌尿道感染%氨曲南%头孢吡肟
泌尿道感染%氨麯南%頭孢吡肟
비뇨도감염%안곡남%두포필우
Urinary tract infections%Aztreonam%Cefepime
目的 分析氨曲南联合头孢吡肟治疗泌尿系统感染的临床疗效.方法 123例泌尿系统感染患者,采用随机区组分组法分为观察组、对照1组和对照2组三组,每组41例.对照1组给予头孢吡肟治疗,对照2组给予氨曲南治疗,观察组则联合给予氨曲南和头孢吡肟,疗程均为7d.结果 观察组总有效率达95.1%,与对照1组(85.4%)和对照2组(82.9%)相比,差异均有统计学意义(x2=12.89、13.56,均P<0.05).治疗结束后,观察组细菌清除率达94.3%,较对照1组和对照2组稍高.各组治疗过程中仅发生轻微不良反应,不影响继续用药,并且停药后症状消失.且各组不良反应发生率差异均无统计学意义(P>0.05).结论 头孢吡肟联合氨曲南用于泌尿系统感染治疗,可提高治疗疗效,且不良反应没有增加.
目的 分析氨麯南聯閤頭孢吡肟治療泌尿繫統感染的臨床療效.方法 123例泌尿繫統感染患者,採用隨機區組分組法分為觀察組、對照1組和對照2組三組,每組41例.對照1組給予頭孢吡肟治療,對照2組給予氨麯南治療,觀察組則聯閤給予氨麯南和頭孢吡肟,療程均為7d.結果 觀察組總有效率達95.1%,與對照1組(85.4%)和對照2組(82.9%)相比,差異均有統計學意義(x2=12.89、13.56,均P<0.05).治療結束後,觀察組細菌清除率達94.3%,較對照1組和對照2組稍高.各組治療過程中僅髮生輕微不良反應,不影響繼續用藥,併且停藥後癥狀消失.且各組不良反應髮生率差異均無統計學意義(P>0.05).結論 頭孢吡肟聯閤氨麯南用于泌尿繫統感染治療,可提高治療療效,且不良反應沒有增加.
목적 분석안곡남연합두포필우치료비뇨계통감염적림상료효.방법 123례비뇨계통감염환자,채용수궤구조분조법분위관찰조、대조1조화대조2조삼조,매조41례.대조1조급여두포필우치료,대조2조급여안곡남치료,관찰조칙연합급여안곡남화두포필우,료정균위7d.결과 관찰조총유효솔체95.1%,여대조1조(85.4%)화대조2조(82.9%)상비,차이균유통계학의의(x2=12.89、13.56,균P<0.05).치료결속후,관찰조세균청제솔체94.3%,교대조1조화대조2조초고.각조치료과정중부발생경미불량반응,불영향계속용약,병차정약후증상소실.차각조불량반응발생솔차이균무통계학의의(P>0.05).결론 두포필우연합안곡남용우비뇨계통감염치료,가제고치료료효,차불량반응몰유증가.
Objective To explore the clinical efficacy of aztreonam in combination with cefepime for the treatment of urinary tract infections.Methods A randomized block grouping,123 cases of urinary tract infections were divided into observation group,aztreonam group and cefepime group,41 cases in each group.The observation group was treated with aztreonam (2.0g) and cefepime (2.0g),control group were given aztreonam and cefepime,respectively.The treatment time lasted 7 days.Results The total effective rate of observation group was 95.1%,compared with cefepime(85.4%)or aztreonam(82.9%) group,the difference was statistically significant(x2 =12.89、13.56,all P < 0.05).After the end of treatment,the observation group bacterial clearance rate (94.3%) was slightly higher than that of cefepime group or aztreonam group.Each group had only minor adverse reaction,which did't affect the continued medication.And the difference in the incidence was not statistically significant(P >0.05).Conclusion Cefepime joint aztreonam in the treatment of urinary tract infection can improve the therapeutic efficacy,and adverse events doesn't increase.